Sugi Predict

Sugi Predict / Compounds / SCHEMBL160715

SCHEMBL160715

SCHEMBL160715

Nc1ccc(CCNC(=O)OCc2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ HTT P42858 1/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ TGM2 P21980 1/20 0.52
▸ SLC1A3 P43003 1/20 0.52
▸ SLC1A1 P43005 1/20 0.52
▸ PLAU P00749 2/20 0.51
▸ KEAP1 Q14145 2/20 0.51
▸ NFE2L2 Q16236 2/20 0.51
▸ HDAC3 O15379 2/20 0.51
▸ HDAC1 Q13547 2/20 0.51
▸ HDAC2 Q92769 2/20 0.51
▸ HDAC4 P56524 1/20 0.51
▸ HDAC7 Q8WUI4 1/20 0.51
▸ HDAC10 Q969S8 1/20 0.51
▸ HDAC11 Q96DB2 1/20 0.51
▸ HDAC8 Q9BY41 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzyl Phenethylcarbamate SCHEMBL4287199 0.91 LMNA (0.73) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL937117 0.90 HTT (0.62) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL6554125 0.88 LMNA (0.65) LMNASMN1; SMN2HTTL3MBTL1MAPT
Benzyl Phenethylcarbamate SCHEMBL6392045 0.86 LMNA (0.67) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL13884390 0.85 LMNA (0.61) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL8802503 0.85 LMNA (0.61) LMNASMN1; SMN2HTTL3MBTL1MAPT
Benzyl Phenethylcarbamate SCHEMBL27338403 0.85 LMNA (0.61) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL9487307 0.85 LMNA (0.61) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL10305302 0.85 LMNA (0.61) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL2851561 0.85 LMNA (0.61) LMNASMN1; SMN2HTTL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117800905-A Preparation method of 4- (2, 6-dimethyl-3-nitropyridin-4-ylamino) phenethyl carbamic acid benzyl ester 洛阳惠中兽药有限公司 2024-04-02 — — CN claimed
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 — — EP disclosed
CN-117800905-A Preparation method of 4- (2, 6-dimethyl-3-nitropyridin-4-ylamino) phenethyl carbamic acid benzyl ester 洛阳惠中兽药有限公司 2024-04-02 — — CN disclosed
CN-117800905-A Preparation method of 4- (2, 6-dimethyl-3-nitropyridin-4-ylamino) phenethyl carbamic acid benzyl ester 洛阳惠中兽药有限公司 2024-04-02 — — CN disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 — — US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 — — US disclosed
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 — — CN disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 — — US disclosed
EP-3814356-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) 2021-05-05 — — EP disclosed
CN-111051309-A Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2020-04-21 — — CN disclosed
EP-1861400-A1 CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE Pfizer, Inc. (US) 2007-12-05 — — EP disclosed
WO-2006095268-A1 CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE PFIZER JAPAN INC. (JP) 2006-09-14 — — WO disclosed
EP-0611003-B1 Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity MERCK & CO INC (US) 1997-06-18 — — EP disclosed
EP-0757674-A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Merck & Co., Inc. (US) 1997-02-12 — — EP disclosed
US-5561142-A Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity MERCK & CO., INC. (US) 1996-10-01 — — US disclosed
US-5541197-A Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity MERCK & CO., INC. (US) 1996-07-30 — — US disclosed
WO-1995029159-A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1995-11-02 — — WO disclosed
US-5451677-A Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity MERCK & CO., INC. (US) 1995-09-19 — — US disclosed
WO-1994018161-A1 SUBSTITUTED PHENYL SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1994-08-18 — — WO disclosed
EP-0611003-A1 Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity MERCK & CO. INC. (US) 1994-08-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 LMNA 3595/4885SMN1; SMN2 4178/4885HTT 2277/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 LMNA 3595/4885SMN1; SMN2 4178/4885HTT 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.